Related Experiment Video
Updated: Aug 6, 2026

Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
Published on: November 27, 2016
Venlafaxine: a structurally unique and novel antidepressant
W A Morton1, S C Sonne, M A Verga
1Department of Hospital Pharmacy Practice and Administration, University of South Carolina Institute of Psychiatry, Charleston, USA.
Venlafaxine is a new antidepressant effective for depression, blocking norepinephrine and serotonin reuptake. Further comparative trials are needed to determine its optimal clinical role.
Area of Science:
- Pharmacology
- Clinical Psychiatry
Background:
- Venlafaxine hydrochloride is a novel antidepressant recently approved in the US.
- It functions by blocking the neuronal reuptake of norepinephrine, serotonin, and dopamine.
Purpose of the Study:
- To introduce the new antidepressant venlafaxine.
- Review pharmacokinetic data, clinical trials, adverse reactions, and drug interactions.
- Compare venlafaxine with other available antidepressants.
Main Methods:
- MEDLINE search for pertinent literature, including reviews.
- Review of all available clinical trials prior to publication.
- Exclusion of preliminary trials and unpublished reports.
Main Results:
- Venlafaxine and its metabolite O-desmethylvenlafaxine exhibit linear kinetics with half-lives of 5 and 11 hours.
- Seven clinical trials demonstrated venlafaxine's efficacy in treating depression.
- Common adverse effects include dry mouth, somnolence, elevated blood pressure, nausea, headache, and dizziness.
Conclusions:
- Few clinical trials exist to guide practitioners on venlafaxine's place in depression treatment.
- Comparative trials against serotonin-specific reuptake inhibitors (SSRIs) are lacking.
- The definitive clinical role of venlafaxine in depression management remains to be established.
More Related Videos
10:17High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Related Concept Videos
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Drugs Affecting Neurotransmitter Release or Uptake
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...